Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in ...

Zynex Inc. ZYXI recently announced the completion of the clinical verification trial of its NiCO pulse oximeter, which was ...

HC Wainwright reissued their buy rating on shares of Zynex (NASDAQ:ZYXI – Free Report) in a report issued on Friday morning,Benzinga reports. The brokerage currently has a $17.00 target price on the ...

Zynex has completed the clinical verification trial of its pulse oximeter, NiCO, marking a significant milestone towards the ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zynex (ZYXI – Research Report) and KalVista ...

Zynex (ZYXI) has completed its clinical verification trial for their NiCO pulse oximeter overseen by anesthesiologist Dr. David MacLeod at Duke ...

Zynex Inc (NASDAQ:ZYXI) holds a competitive niche in the pain management market, benefiting from its focus on non-invasive, ...

Check the time stamp on this data. Updated AI-Generated Signals for Zynex Inc. (ZYXI) available here: ZYXI.

To keep the lesson grounded in practicality, we'll use ROE to better understand Zynex, Inc. (NASDAQ:ZYXI). ROE or return on equity is a useful tool to assess how effectively a company can generate ...

ENGLEWOOD, CO—Thomas Sandgaard, the President, CEO, and Chairman of Zynex Inc. (NASDAQ:ZYXI), recently executed a series of stock sales totaling $89,280. The transactions, disclosed in a recent SEC ...